Toll Biotech Co. Ltd. (beijing)

This study tests a new oral drug, TollB-001, in 24 adults aged 18-70 with moderate to severe active rheumatoid arthritis who haven't responded well to standard treatments. Participants take either the drug or a placebo once daily for 4 weeks, with a 1-week follow-up. The goal is …